Experts divided on Avrobio’s phase two gene therapy for Fabry disease
Trending menu:
Latest Content
Abivax gets FDA approval to conduct Phase IIb ulcerative colitis study
The US Food and Drug Administration (FDA) has approved Abivax’s investigational new drug (IND) application for ABX464 to treat moderate-to-severe ulcerative colitis (UC).
Abivax to expand Phase IIb ulcerative colitis trial to France
Abivax has received approval from the French National Regulatory Authority (ANSM) to conduct its Phase IIb clinical trial of ABX464 to treat moderate-to-severe active ulcerative colitis (UC) patients in the country.
Provention Bio reports mixed results from Crohn’s disease study
Provention Bio has announced top-line data from the Phase IIa clinical trial conducted to evaluate its investigational drug PRV-6527 for the treatment of moderate to severe Crohn's disease.
Janssen reports two-year UNIFI data for Stelara in ulcerative colitis
Janssen Pharmaceutical has reported two-year results from the long-term extension of the Phase III UNIFI clinical trial of Stelara (ustekinumab) in adults with moderately to severely active ulcerative colitis (UC).
Takeda reports further results from VARSITY ulcerative colitis study
Takeda Pharmaceutical has reported further results from the VARSITY study, which indicated the gut-selective biologic vedolizumab (Entyvio) being superior to the anti-tumor necrosis factor-alpha (anti-TNFα) biologic adalimumab (Humira) for ulcerative colitis.
Could PF-06480605 Phase IIb trial registration pave the way for Pfizer’s dominance in UC space?
Pfizer's PF-06480605 is an antibody that blocks tumour necrosis factor.
JAK inhibitor ulcerative colitis trial delays triggered by the paucity of eligible patients
According to experts, biologic-naïve patients usually enrolled along with pretreated patients, are harder to recruit.
Janssen starts dosing in REEF-1 Phase IIb trial to treat hepatitis B
Arrowhead Pharmaceuticals has announced that Janssen has started dosing in a REEF-1 Phase IIb study of different combination regimens, including JNJ-3989, and/or JNJ-6379, and a nucleos(t)ide analogue (NA) to treat patients with chronic hepatitis B virus (HBV) infection.
Acurx finishes trial of ACX-362E in clostridioides difficile infection
Clinical stage biopharmaceutical company Acurx Pharmaceuticals has completed the Phase I trial of ACX-362E for the treatment of clostridioides difficile infection (CDI).
Related Treatments
Close
Close
Close
Go Top